Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 ...
An ambitious form of climate modelling aims to pin the blame for disasters – from floods to heatwaves – on specific companies ...
Canadian International School will host the 11th edition of its Juniors Golf Tournament for students. Choose from any one of ...
Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).
The Cut on MSN
When your son abuses your daughter
Sibling sexual abuse forces parents to make an impossible choice: Do they forsake one child to protect the other?
Rankings, record placements, and rigid rules define Chandigarh University’s rapid ascent to India's top ranked private ...
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Face swapping used to sound like something complicated that only professionals could do. Not anymore. Thanks to AI-powered online tools, anyone can experiment with creative edits and produce fun, ...
GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
Get ready for an action-packed year with the VMI Keydets! This season promises some exciting matchups across multiple sports, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback